Abstract
The aim of our study was to evaluate the efficacy and safety in unresectable or advanced renal carcinoma treated with sorafenib, in a situation closely similar to the everyday medical practice. One hundred and thirty-six patients have been treated with 400 mg b.i.d. of sorafenib administered orally until disease progression or unacceptable toxicity. They were either previously untreated or relapsed after one or more previous treatments with systemic therapy. Most of them had clear cell renal carcinoma (RCC), but other histological types such as papillary, chromophobe, Bellini ducts, sarcomatoid and mixed forms were also represented. Overall disease control of 70.6% was achieved with 7.9% of partial remissions. Response was observed in the majority of patients with RCC, but also in some patients with non-clear cell RCC. Safety was acceptable, with the most common adverse events consisting of hand-foot skin reaction, cutaneous rash, diarrhoea, fatigue and hypertension. The results confirm previous ones reported in the literature concerning the efficacy and the safety of sorafenib as second-line treatment in patients with RCC. In addition, they disclose the hypothesis that sorafenib could be effective also in patients who underwen...Continue Reading
Citations
Jan 5, 2011·Anti-cancer Drugs·Pedro SánchezIgnacio Durán
Oct 27, 2010·Journal of Medical Case Reports·Thomas Sarkodie, Paul Ross
Aug 11, 2010·European Journal of Medical Research·Michael StaehlerC G Stief
Jun 26, 2012·La Presse médicale·Marion CastelAtul Pathak
Sep 29, 2011·Critical Reviews in Oncology/hematology·Fable ZustovichDavide Pastorelli
Apr 26, 2011·Oral Oncology·A L WattersM Agulnik
Jun 13, 2009·Journal of the American College of Cardiology·Edward T H Yeh, Courtney L Bickford
Apr 2, 2015·PloS One·Mayer N FishmanPamela K Foreman
Dec 13, 2016·International Journal of Molecular Sciences·Aleksandra Semeniuk-WojtaśStanisław Niemczyk
Jun 26, 2015·Tumori·Elena VerzoniGiuseppe Procopio
Oct 30, 2016·Tumori·Alessia MennittoGiuseppe Procopio
Aug 28, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Robert J Cersosimo
Aug 8, 2021·Cancers·Pierangela SepeGiuseppe Procopio
Jan 1, 2020·Kidney Cancer·Chelsea K Osterman, Tracy L Rose